WO1997046584A1
(de)
*
|
1996-06-05 |
1997-12-11 |
Boehringer Mannheim Gmbh |
Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
|
CA2262647C
(en)
|
1996-08-08 |
2007-12-04 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
ES2237790T3
(es)
*
|
1996-11-12 |
2005-08-01 |
Novo Nordisk A/S |
Uso de peptidos glp-1.
|
ES2247676T3
(es)
|
1997-01-07 |
2006-03-01 |
Amylin Pharmaceuticals, Inc. |
Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
|
US20040022807A1
(en)
*
|
1998-06-05 |
2004-02-05 |
Duft Bradford J |
Methods for treating obesity
|
US7910548B2
(en)
*
|
1997-06-06 |
2011-03-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
BR9811866A
(pt)
*
|
1997-08-08 |
2000-08-15 |
Amylin Pharmaceuticals Inc |
Compostos agonistas de exendina
|
EP1938831A1
(de)
*
|
1997-08-08 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Neue Exendinagonist-Verbindungen
|
EP1941900A1
(de)
*
|
1997-11-14 |
2008-07-09 |
Amylin Pharmaceuticals, Inc. |
Neue Exendinagonist-Verbindungen
|
BR9815670A
(pt)
|
1997-11-14 |
2000-10-17 |
Amylin Pharmaceuticals Inc |
Compostos agonistas de exendina
|
AU2003200129B2
(en)
*
|
1997-11-14 |
2006-06-22 |
Amylin Pharmaceuticals, Llc |
Novel Exendin Agonist Compounds
|
DK1032587T4
(da)
*
|
1997-11-14 |
2013-04-08 |
Amylin Pharmaceuticals Llc |
Hidtil ukendte exendinagonist-forbindelser
|
AU2006225176B2
(en)
*
|
1997-11-14 |
2009-01-08 |
Amylin Pharmaceuticals, Llc |
Novel exendin agonist compounds
|
EP1938830A1
(de)
*
|
1997-11-14 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Neue Exendinagonist-Verbindungen
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
US6284725B1
(en)
*
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
ES2343072T3
(es)
|
1999-01-14 |
2010-07-22 |
Amylin Pharmaceuticals, Inc. |
Exendina para la supresion del glucagon.
|
US20030087820A1
(en)
*
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
DE122007000001I1
(de)
*
|
1999-01-14 |
2007-06-28 |
Amylin Pharmaceuticals Inc |
Neue exendin agonist Formulierungen und deren Verabreichung
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
AU775063C
(en)
|
1999-04-30 |
2005-05-12 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US6506724B1
(en)
*
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
EP1076066A1
(de)
*
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptide zur Senkung des Blutglukosespiegels
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1246638B2
(de)
*
|
2000-01-10 |
2014-07-30 |
Amylin Pharmaceuticals, Inc. |
Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
|
JP2003525908A
(ja)
*
|
2000-03-08 |
2003-09-02 |
ノボ ノルディスク アクティーゼルスカブ |
血清脂質の低下
|
CA2431800C
(en)
|
2000-12-14 |
2014-07-08 |
Amylin Pharmaceuticals, Inc. |
Peptide yy and peptide yy agonists for treatment of metabolic disorders
|
US20090281032A1
(en)
*
|
2001-03-01 |
2009-11-12 |
Peter Raymond Flatt |
Modified CCK peptides
|
EP2275117B1
(de)
|
2001-07-31 |
2016-10-26 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
GLP-1, Exendin-4, Peptid-Analoga und Verwendungen davon
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
DE60230818D1
(de)
*
|
2001-09-24 |
2009-02-26 |
Imp Innovations Ltd |
Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
|
EP1461069A2
(de)
*
|
2001-12-29 |
2004-09-29 |
Novo Nordisk A/S |
Kombinierte verwendung einer glp-1-verbindung und eines anderes medikaments zur behandlungv on dyslipidämie
|
ES2316757T3
(es)
*
|
2002-01-08 |
2009-04-16 |
Amylin Pharmaceuticals, Inc. |
Uso de agonistas de amilina para modular trigliceridos.
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
EP1474163A2
(de)
*
|
2002-01-10 |
2004-11-10 |
Imperial College Innovations Limited |
Veränderung des fütterungsverhaltens
|
US7105489B2
(en)
*
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
DE60327771D1
(de)
|
2002-07-04 |
2009-07-09 |
Zealand Pharma As |
Glp-1 und behandlungsmethode für diabetes
|
EP1546200A2
(de)
|
2002-10-02 |
2005-06-29 |
Zealand Pharma A/S |
Stabilisierte exendin-4-verbindungen
|
US7164005B2
(en)
*
|
2002-10-17 |
2007-01-16 |
Alkermes, Inc. |
Microencapsulation and sustained release of biologically active polypeptides
|
DE60326002D1
(de)
*
|
2002-10-22 |
2009-03-12 |
Waratah Pharmaceuticals Inc |
Behandlung von diabetes.
|
WO2004050115A2
(en)
*
|
2002-12-03 |
2004-06-17 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
EP1581247A4
(de)
*
|
2002-12-11 |
2007-09-12 |
Amylin Pharmaceuticals Inc |
Verfahren und zusammensetzungen zur behandlung des stein-leventhal-syndroms
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US20040209803A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
EP1631308B1
(de)
*
|
2003-05-30 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Neue verfahren und zusammensetzungen für die verbesserte transmukosale abgabe von peptiden und proteinen
|
WO2005021026A2
(en)
*
|
2003-08-29 |
2005-03-10 |
Amylin Pharmaceuticals, Inc. |
Methods for treating or ameliorating ghrelin-associated diseases and disorders
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
US8263084B2
(en)
*
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
KR101135244B1
(ko)
|
2007-11-29 |
2012-04-24 |
한미사이언스 주식회사 |
인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
|
WO2005046716A1
(en)
*
|
2003-11-13 |
2005-05-26 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
|
CN104826116A
(zh)
|
2003-11-20 |
2015-08-12 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
EP1694356B1
(de)
*
|
2003-12-09 |
2011-02-16 |
Novo Nordisk A/S |
Regulierung der nahrungspräferenz mit glp-1-agonisten
|
EP2417980A1
(de)
*
|
2004-02-11 |
2012-02-15 |
Amylin Pharmaceuticals Inc. |
Hybridpolypeptide mit auswahlbaren Eigenschaften
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
RU2385878C2
(ru)
|
2004-02-11 |
2010-04-10 |
Амилин Фармасьютикалз, Инк. |
Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
|
PL1745078T3
(pl)
|
2004-04-23 |
2009-12-31 |
Conjuchem Biotechnologies Inc |
Sposób oczyszczania koniugatów albumin
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
CN1950078A
(zh)
*
|
2004-06-11 |
2007-04-18 |
诺和诺德公司 |
使用glp-1激动剂抵抗药物诱发的肥胖
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP1814590B2
(de)
|
2004-11-01 |
2013-12-11 |
Amylin Pharmaceuticals, Inc. |
Behandlung von fettsucht und verbundenen erkrankungen
|
AU2005305036B2
(en)
*
|
2004-11-01 |
2011-03-10 |
Amylin Pharmaceuticals, Llc |
Treatment of obesity and related disorders
|
WO2006074051A2
(en)
*
|
2004-12-30 |
2006-07-13 |
Diakine Therapeutics, Inc. |
PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
US20090286723A1
(en)
*
|
2005-02-11 |
2009-11-19 |
Amylin Pharmaceuticals, Inc. |
Hybrid Polypeptides with Selectable Properties
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
CA2597649A1
(en)
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
JP4584331B2
(ja)
*
|
2005-03-11 |
2010-11-17 |
インデバス ファーマシューティカルズ、インク. |
オクトレオチドの放出制御製剤
|
US7759312B2
(en)
*
|
2005-03-11 |
2010-07-20 |
Endo Pharmaceuticals Solutions Inc. |
Delivery of dry formulations of octreotide
|
JP5114381B2
(ja)
*
|
2005-03-31 |
2013-01-09 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
精神疾患および障害治療用アミリンおよびアミリンアゴニスト
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
US20090239796A1
(en)
|
2005-08-19 |
2009-09-24 |
Amylin Pharmaceuticals, Inc. |
Methods for treating diabetes and reducing body weight
|
US8389472B2
(en)
|
2005-08-19 |
2013-03-05 |
Amylin Pharmaceuticals, Llc |
Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
|
BRPI0617621A2
(pt)
|
2005-10-21 |
2011-08-02 |
Novartis Ag |
combinação de compostos orgánicos
|
WO2007055743A2
(en)
*
|
2005-11-01 |
2007-05-18 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and related disorders
|
AU2006312307A1
(en)
*
|
2005-11-01 |
2007-05-18 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and related disorders
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
ES2384032T3
(es)
*
|
2005-11-29 |
2012-06-28 |
Kolon Industries, Inc. |
Una membrana de fibra hueca compuesta reforzada mediante malla
|
WO2007071068A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Conjuchem Biotechnologies Inc. |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
BRPI0712559A2
(pt)
*
|
2006-05-26 |
2012-11-20 |
Amylin Pharmaceuticals Inc |
composiÇÕes e mÉtodos para o tratamento de insuficiÊncia cardÍaca congestiva
|
ES2351527T3
(es)
|
2006-05-30 |
2011-02-07 |
Intarcia Therapeutics, Inc |
Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
|
EP2046826B1
(de)
|
2006-07-24 |
2011-09-14 |
Biorexis Pharmaceutical Corporation |
Exendin-fusionsproteine
|
US20090209469A1
(en)
*
|
2006-08-04 |
2009-08-20 |
Dennis Kim |
Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
|
WO2008019147A2
(en)
*
|
2006-08-04 |
2008-02-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
|
NZ574524A
(en)
|
2006-08-09 |
2011-07-29 |
Intarcia Therapeutics Inc |
Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
AU2007285827A1
(en)
*
|
2006-08-17 |
2008-02-21 |
Wellstat Therapeutics Corporation |
Combination treatment for metabolic disorders
|
US20090318353A1
(en)
*
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
KR100872304B1
(ko)
*
|
2006-11-28 |
2008-12-05 |
주식회사 코오롱 |
편물로 보강된 복합 중공사막
|
TWI428346B
(zh)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
EP2157967B1
(de)
|
2007-04-23 |
2013-01-16 |
Intarcia Therapeutics, Inc |
Suspensionsformulierungen insulinotroper peptide und ihre verwendung
|
JP2009019027A
(ja)
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
|
BRPI0722276A2
(pt)
*
|
2007-11-14 |
2014-04-22 |
Amylin Pharmaceuticals Inc |
Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
|
WO2009075859A2
(en)
*
|
2007-12-11 |
2009-06-18 |
Conjuchem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
WO2009102467A2
(en)
|
2008-02-13 |
2009-08-20 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
EP2259791A2
(de)
*
|
2008-03-05 |
2010-12-15 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Glp-1-rezeptoragonisten und zugehörige pharmazeutische wirkstoffe zur behandlung von krebs
|
WO2009143285A2
(en)
|
2008-05-21 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholestrol and triglycerides
|
WO2009158415A1
(en)
|
2008-06-25 |
2009-12-30 |
Endo Pharmaceuticals Solutions Inc. |
Octreotide implant having a release agent
|
WO2009158412A2
(en)
*
|
2008-06-25 |
2009-12-30 |
Endo Pharmaceuticals Solutions Inc. |
Sustained delivery of exenatide and other polypeptides
|
JP2011528709A
(ja)
*
|
2008-07-21 |
2011-11-24 |
トランスファーマ メディカル リミテッド |
インクレチンおよびインクレチン模倣ペプチドの持続性送達用経皮システム
|
KR101760953B1
(ko)
|
2008-09-04 |
2017-07-24 |
아밀린 파마슈티칼스, 엘엘씨. |
비-수성 담체를 이용한 서방성 제형물
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
WO2010043566A2
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem insulin und einem glp-1-agonisten
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
US20120231022A1
(en)
|
2009-05-28 |
2012-09-13 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
LT2462246T
(lt)
|
2009-09-28 |
2017-11-27 |
Intarcia Therapeutics, Inc |
Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
|
US20120294855A1
(en)
*
|
2009-11-03 |
2012-11-22 |
Eli Lilly & Company |
Glp-1 receptor agonist compounds for obstructive sleep apnea
|
US9707176B2
(en)
|
2009-11-13 |
2017-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist and methionine
|
DE102010011919A1
(de)
|
2010-03-18 |
2011-09-22 |
Sanofi-Aventis Deutschland Gmbh |
Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
|
ES2855146T3
(es)
|
2009-11-13 |
2021-09-23 |
Sanofi Aventis Deutschland |
Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
|
EP2504019A2
(de)
|
2009-11-25 |
2012-10-03 |
ArisGen SA |
Zusammensetzung zur verabreichung über die schleimhaut mit einem komplex aus einem peptid und einer kronenverbindung und/oder einem gegenion
|
CN102100912B
(zh)
*
|
2009-12-16 |
2015-04-22 |
上海蓝心医药科技有限公司 |
一种给药组合物及其制备和使用方法
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
MX343360B
(es)
|
2010-04-27 |
2016-11-03 |
Zealand Pharma As |
Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
PT2611458T
(pt)
|
2010-08-30 |
2016-12-16 |
Sanofi Aventis Deutschland |
Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
CN103370083B
(zh)
|
2010-09-28 |
2016-11-16 |
艾米琳制药有限责任公司 |
具有增强的作用持续时间的工程化多肽
|
WO2012088157A2
(en)
|
2010-12-22 |
2012-06-28 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonists for islet cell transplantation
|
AU2012205301B2
(en)
|
2011-01-14 |
2017-01-05 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CN108676076A
(zh)
|
2011-03-01 |
2018-10-19 |
辛纳吉制药公司 |
制备鸟苷酸环化酶c激动剂的方法
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
WO2012162547A2
(en)
|
2011-05-25 |
2012-11-29 |
Amylin Pharmaceuticals, Inc. |
Long duration dual hormone conjugates
|
US9278910B2
(en)
|
2011-05-31 |
2016-03-08 |
Receptos, Inc. |
GLP-1 receptor stabilizers and modulators
|
WO2013004983A1
(en)
|
2011-07-04 |
2013-01-10 |
Imperial Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
WO2013009545A1
(en)
|
2011-07-08 |
2013-01-17 |
Amylin Pharmaceuticals, Inc. |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
PT2750699E
(pt)
|
2011-08-29 |
2015-11-03 |
Sanofi Aventis Deutschland |
Acelerómetro pendular
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
WO2013050378A1
(en)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
EP2763690B1
(de)
|
2011-10-04 |
2015-11-25 |
Sanofi-Aventis Deutschland GmbH |
Lixisenatide zur behandlung von stenosen oder/und obstruktionen im pankreasgangsystem
|
CN104144704B
(zh)
|
2011-11-03 |
2018-03-23 |
西兰制药公司 |
Glp‑1受体激动剂肽胃泌素缀合物
|
JP6061949B2
(ja)
|
2011-12-12 |
2017-01-18 |
レセプトス エルエルシー |
糖尿病などの疾患の治療のためのglp−1受容体モジュレーターとして作用する4つの環を含むカルボン酸誘導体
|
AR091422A1
(es)
|
2012-06-14 |
2015-02-04 |
Sanofi Sa |
Analogos peptidicos de la exendina 4
|
AR091866A1
(es)
|
2012-07-23 |
2015-03-04 |
Zealand Pharma As |
Analogos del glucagon
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
ES2688367T3
(es)
|
2012-12-21 |
2018-11-02 |
Sanofi |
Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
|
KR101581497B1
(ko)
|
2013-01-24 |
2015-12-30 |
강원대학교산학협력단 |
인삼열매 추출물을 포함하는 파킨슨병과 알츠하이머병의 예방 또는 치료용 조성물
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
EP2968471B1
(de)
|
2013-03-01 |
2017-07-19 |
Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca |
Peptide zur verwendung in der topischen behandlung von neurodegenerativen erkrankungen der netzhaut, insbesondere in frühen stadien von diabetischer retinopathie und/oder netzhauterkrankungen mit neurodegeneration als wichtigem faktor
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
EA030857B1
(ru)
|
2013-06-11 |
2018-10-31 |
Селджин Интернэшнл Ii Сарл |
Новые модуляторы рецептора glp-1
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
UA122767C2
(uk)
|
2013-10-17 |
2021-01-06 |
Зіленд Фарма А/С |
Ацильований аналог глюкагону
|
WO2015063613A2
(en)
|
2013-11-01 |
2015-05-07 |
Spherium Biomed S.L. |
Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
|
CA2929459C
(en)
|
2013-11-06 |
2022-05-03 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
EA035688B1
(ru)
|
2013-11-06 |
2020-07-27 |
Зилэнд Фарма А/С |
Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
EP3080154B1
(de)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Duale glp-1/gip-rezeptoragonisten
|
EP3080152A1
(de)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Nicht-acylierte exendin-4-peptidanaloga
|
WO2015104311A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
CN112957455A
(zh)
|
2014-01-09 |
2021-06-15 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
SG11201700364PA
(en)
|
2014-07-25 |
2017-02-27 |
Celgene Internat Ii Sarl |
Novel glp-1 receptor modulators
|
RU2573933C1
(ru)
|
2014-08-21 |
2016-01-27 |
Дафот Энтерпрайсис Лимитед |
Пептид для лечения сахарного диабета 2-го типа и его осложнений
|
JP6769963B2
(ja)
|
2014-08-29 |
2020-10-14 |
ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ |
α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
BR112017008659A2
(pt)
|
2014-10-29 |
2018-01-30 |
Zealand Pharma As |
?métodos e compostos de agonista de gip?
|
EP3230276B1
(de)
|
2014-12-10 |
2020-09-02 |
Celgene International II Sarl |
Glp-1-rezeptormodulatoren
|
CN107206058A
(zh)
|
2014-12-12 |
2017-09-26 |
赛诺菲-安万特德国有限公司 |
甘精胰岛素/利西拉来固定比率配制剂
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
AU2016247499B2
(en)
|
2015-04-16 |
2020-09-03 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
LT3297653T
(lt)
|
2015-05-22 |
2022-01-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
|
JP6993235B2
(ja)
|
2015-06-03 |
2022-01-13 |
インターシア セラピューティクス,インコーポレイティド |
インプラントの設置及び撤去システム
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
|
US10677956B2
(en)
*
|
2015-10-01 |
2020-06-09 |
Schlumberger Technology Corporation |
Active damping for NMR logging tools
|
EP3370518B1
(de)
|
2015-10-14 |
2023-08-23 |
X-Therma, Inc. |
Zusammensetzungen und verfahren zur verringerung der eiskristallbildung
|
WO2017112824A2
(en)
|
2015-12-23 |
2017-06-29 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
US10653753B2
(en)
|
2016-03-04 |
2020-05-19 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
|
WO2017181007A1
(en)
*
|
2016-04-15 |
2017-10-19 |
Robert Doyle |
Peptide drug improvement using vitamin b12 and haptocorrin binding substrate conjugates
|
AU2017257504A1
(en)
|
2016-04-26 |
2018-10-25 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
EP3458084B1
(de)
|
2016-05-16 |
2020-04-01 |
Intarcia Therapeutics, Inc |
Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
US20190224122A1
(en)
|
2016-09-23 |
2019-07-25 |
Delpor, Inc. |
Stable compositions for incretin mimetic compounds
|
AU2017342083A1
(en)
|
2016-10-14 |
2019-04-11 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
BR112019010236A2
(pt)
|
2016-11-21 |
2019-08-20 |
Eiger Biopharmaceuticals Inc |
formulações tamponadas de exendina (9-39)
|
WO2018104263A1
(en)
|
2016-12-06 |
2018-06-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
|
CN117384274A
(zh)
|
2016-12-09 |
2024-01-12 |
西兰制药公司 |
酰化的glp-1/glp-2双重激动剂
|
KR20190104039A
(ko)
|
2017-01-03 |
2019-09-05 |
인타르시아 세라퓨틱스 인코포레이티드 |
Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
CA3058806A1
(en)
|
2017-04-03 |
2018-10-11 |
Coherus Biosciences Inc. |
Ppar.gamma. agonist for treatment of progressive supranuclear palsy
|
EP3642239A1
(de)
|
2017-06-20 |
2020-04-29 |
Amgen Inc. |
Verfahren zur behandlung oder linderung von stoffwechselstörungen mit bindenden proteinen für magensäureinhibierenden peptidrezeptor (gipr) in kombination mit glp-1-agonisten
|
TWI762706B
(zh)
|
2017-08-24 |
2022-05-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1組成物及其用途
|
WO2019197469A1
(en)
|
2018-04-10 |
2019-10-17 |
Sanofi-Aventis Deutschland Gmbh |
Lixisenatide synthesis with capping
|
CN112543763A
(zh)
|
2018-04-10 |
2021-03-23 |
赛诺菲-安万特德国有限公司 |
从固相裂解固相结合肽的方法
|
KR20210111248A
(ko)
|
2018-11-20 |
2021-09-10 |
테스 파마 에스.알.엘. |
α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
|
EP3934679A1
(de)
|
2019-03-08 |
2022-01-12 |
Amgen Inc. |
Kombinationstherapie mit wachstumsdifferenzierungsfaktor 15
|
WO2021144476A1
(en)
|
2020-02-18 |
2021-07-22 |
Novo Nordisk A/S |
Pharmaceutical formulations
|